Enochian Biosciences is a pre-clinical stage biotechnology company committed to using its genetically modified cellular and immune-therapy technologies to prevent or potentially cure HIV and to potentially provide life-long cancer remission of some of the deadliest cancers. We do this by genetically modifying, or re-engineering, different types of cells, depending on the therapeutic area, and then injecting or reinfusing the re-engineered cells back into the patient to provide treatment. Enochianâs lead candidate ENOB-HV-01 (pre-IND) is a treatment for HIV/AIDS. Enochian has developed ENOB-HV-11 and ENOB-HV-12 that will utilize a novel cellular- and immunotherapy approach to potentially provide for a preventative vaccine and a therapeutic vaccine, respectively. Enochian is developing an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors. The Company plans to initially target pancreatic cancer, triple negative breast cancer, glioblastoma, and renal cell carcinoma. The platform may also allow for non-specific immune enhancement that could have impact against a broad array of solid tumors. As with HIV, this approach would potentially allow for outpatient therapy without ablating or significantly impairing the patientâs immune system, as many current approaches require.
Source
